Published online Sep 16, 2021. doi: 10.12998/wjcc.v9.i26.7682
Peer-review started: February 23, 2021
First decision: March 25, 2021
Revised: April 2, 2021
Accepted: July 27, 2021
Article in press: July 27, 2021
Published online: September 16, 2021
There are no studies on the use of roxadustat in patients on regular peritoneal dialysis in China.
The recombinant human erythropoietin (EPO) is mainly used to treat renal anemia in peritoneal dialysis patients, but the treatment compliance rate is not satisfactory.
Roxadustat (hypoxia-inducible factor prolyl hydroxylase inhibitor) is a new generation of oral anaemia treatment drug that can effectively correct renal anaemia in non-dialysis and hemodialysis patients. We aimed to research if roxadustat could further improve the compliance of anemia treatment in peritoneal dialysis patients.
This was a retrospective study to evaluate the efficacy of roxadustat in the treatment of peritoneal dialysis patients with renal anaemia. A before-and-after self-control design was performed on 31 patients treated with recombinant human EPO followed by roxadustat.
The haemoglobin (Hb) compliance rate was 16.1% during the EPO phase and 67.7% during the roxadustat phase. Roxadustat also affected the iron reserves and blood lipids. No major adverse cardiovascular events or exacerbation of hypertension occurred in any patient.
The application of roxadustat in peritoneal dialysis patients with renal anaemia can effectively improve the Hb compliance rate.
Roxadustat could safely and effectively improve the anemia in peritoneal dialysis patients, and the mechanisms underlying the effects on or interactions with lipids, iron reserves, and inflammation require further clarification.